DE2318512A1 - Piperidinderivate und ihre verwendung in der humantherapie - Google Patents
Piperidinderivate und ihre verwendung in der humantherapieInfo
- Publication number
- DE2318512A1 DE2318512A1 DE19732318512 DE2318512A DE2318512A1 DE 2318512 A1 DE2318512 A1 DE 2318512A1 DE 19732318512 DE19732318512 DE 19732318512 DE 2318512 A DE2318512 A DE 2318512A DE 2318512 A1 DE2318512 A1 DE 2318512A1
- Authority
- DE
- Germany
- Prior art keywords
- diet
- group
- nicotinic acid
- animals
- merochinen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 11
- 150000003053 piperidines Chemical class 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 206010021024 Hypolipidaemia Diseases 0.000 claims 1
- 239000013061 administrable dose form Substances 0.000 claims 1
- 230000036035 hypolipemia Effects 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 30
- 230000037213 diet Effects 0.000 description 19
- 235000005911 diet Nutrition 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 16
- 235000001968 nicotinic acid Nutrition 0.000 description 15
- 229960003512 nicotinic acid Drugs 0.000 description 15
- 239000011664 nicotinic acid Substances 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000002093 peripheral effect Effects 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000000304 vasodilatating effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000000923 atherogenic effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000002468 fat body Anatomy 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- -1 4-piperidyl vinegar acid Chemical compound 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000000871 hypocholesterolemic effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical class OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- PVJGZBJPNNWIHT-UHFFFAOYSA-N 1-piperidin-4-ylpentan-3-one Chemical compound CCC(=O)CCC1CCNCC1 PVJGZBJPNNWIHT-UHFFFAOYSA-N 0.000 description 1
- YFNOTMRKVGZZNF-UHFFFAOYSA-N 2-piperidin-1-ium-4-ylacetate Chemical compound OC(=O)CC1CCNCC1 YFNOTMRKVGZZNF-UHFFFAOYSA-N 0.000 description 1
- ZSFHGXOMOOJAGZ-UHFFFAOYSA-N 2-piperidin-1-ium-4-ylpropanoate Chemical compound OC(=O)C(C)C1CCNCC1 ZSFHGXOMOOJAGZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001584785 Anavitrinella pampinaria Species 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- ORGHESHFQPYLAO-UHFFFAOYSA-N vinyl radical Chemical compound C=[CH] ORGHESHFQPYLAO-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1698072A GB1435912A (en) | 1972-04-12 | 1972-04-12 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2318512A1 true DE2318512A1 (de) | 1973-10-25 |
Family
ID=10087066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732318512 Pending DE2318512A1 (de) | 1972-04-12 | 1973-04-12 | Piperidinderivate und ihre verwendung in der humantherapie |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE797853A (enrdf_load_stackoverflow) |
| DE (1) | DE2318512A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2179792B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1435912A (enrdf_load_stackoverflow) |
| NL (1) | NL7305156A (enrdf_load_stackoverflow) |
-
1972
- 1972-04-12 GB GB1698072A patent/GB1435912A/en not_active Expired
-
1973
- 1973-04-03 FR FR7311885A patent/FR2179792B1/fr not_active Expired
- 1973-04-06 BE BE129707A patent/BE797853A/xx unknown
- 1973-04-12 DE DE19732318512 patent/DE2318512A1/de active Pending
- 1973-04-12 NL NL7305156A patent/NL7305156A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE797853A (fr) | 1973-07-31 |
| GB1435912A (en) | 1976-05-19 |
| FR2179792A1 (enrdf_load_stackoverflow) | 1973-11-23 |
| NL7305156A (enrdf_load_stackoverflow) | 1973-10-16 |
| FR2179792B1 (enrdf_load_stackoverflow) | 1976-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2635853C2 (de) | Pyrrolidin-2-on-Derivate und diese enthaltende Arzneimittel | |
| DE2815578C2 (de) | Neue pharmazeutische Verwendung von Nimodipin | |
| DE3027039A1 (de) | Pharmazeutischer ansatz mit einer corticosteroid-substanz | |
| DE3854121T2 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
| DE69826674T2 (de) | Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend | |
| DE3000139C2 (de) | Verwendung von Glyzerinphosphorylderivaten zur Behandlung der Dislipämie, der akuten, subakuten oder chronischen Hepatitis und der Steatose | |
| DE2157272C3 (de) | Verwendung von bis-(p-Chlorphenoxy)acetylharnstoff | |
| DE2851416A1 (de) | 2-(4-biphenylyl)-n-(diethylaminoalkyl)- propionamide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| DE2318512A1 (de) | Piperidinderivate und ihre verwendung in der humantherapie | |
| DE2525064C2 (de) | Arzneimittel mit Antiparkinson-Wirkung | |
| DE2748291B2 (de) | Substituierte 13-Benzodioxan-4one und Verfahren zu ihrer Herstellung sowie Verwendung dieser Verbindungen bei der Bekämpfung von Entzündungen | |
| DE2461069B2 (de) | 2-(4-Benzylphenoxy)-alkancarbonsäureester, Verfahren zu ihrer Herstellung und diese Ester enthaltende Arzneimittel | |
| DE1770187C3 (de) | 4- [N-Allyl-N-(2' methoxycarbonylphenyl)-amino eckige Klammer zu -7-chlorchinoIin, Verfahren zu seiner Herstellung und therapeutische Zusammensetzungen | |
| DE2520483A1 (de) | Phenoxy-isobuttersaeurederivate und diese verbindungen enthaltende arzneimittel | |
| DE2502679C3 (de) | Phenoxyalkancarbonsäurederivate, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE3315877A1 (de) | N-oxide von pyridyl-carbonsaeureestern, ein verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten | |
| DE2351292B2 (de) | 2,10-Dichlor-6-äthoxycarbonyl-12- methyl-12Hdibenzo [d,g] [13] dioxocin und Verfahren zu dessen Herstellung sowie diese Verbindung enthaltende Arzneimittel | |
| DE1470012B2 (de) | Papaverinsalz der 7-theophyllin-n- propan-omega-sulfonsaeure | |
| DE1695832C3 (de) | B1,3-biphenylpyrazolin-Derivate und Verfahren zu ihrer Herstellung | |
| DE1695043C2 (de) | Pharmazeutische Zusammensetzungen mit sedativen und tranquillisierenden Eigenschaften | |
| DE2625221A1 (de) | Arzneimittel | |
| DE1770429B2 (de) | In 1-Stellung basisch substituierte 33-Diphenylpyridazone-6 | |
| DE1291748B (de) | 1, 3-Dioxan-2-carbonsaeuren und deren Alkalisalze sowie Verfahren zu deren Herstellung | |
| DE1695907C3 (de) | Verwendung von 3,5-Dimethyl-l,2oxazinon-(6) | |
| DE2500599A1 (de) | Vincamin-2-ketoglutarat und verfahren zu seiner herstellung |